my personal edition > renal failure > news
E-Mail this DGDispatch to a colleague
DGDispatch
Atorvastatin Improves Inflammatory State of Patients with Chronic Kidney Disease: Presented at ASN
By Maria Bishop
PHILADELPHIA, PA -- November 14, 2005 -- Atorvastatin treatment improves the inflammatory state of patients with chronic kidney disease, with no effect on fibrinolytic balance, noted researchers here on at the 38th Annual Meeting and Scientific Exposition of the American Society of Nephrology (ASN).
After 6 months of atorvastatin treatment, total cholesterol and low-density lipoprotein (LDL) cholesterol were significantly reduced in patients with estimated glomerular filtration rate (GFR) between 15 and 90 mL/min.
Jose Luno, MD, Nephrology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain, presented the findings on November 10th.
All 47 subjects in the study had LDL-cholesterol levels >100 mg/dL, had not been treated with statins during the previous 3 months, and had no cardiovascular event during the same period.
Besides a hypolipidemic effect, the team observed significant reductions in C reactive protein and interleukin 1 levels. The researchers also observed a trend toward reduction of tumor-necrosis factor alfa levels.
There was no change in levels of high-density lipoprotein cholesterol, triglycerides, tissue plasminogen activator and plasminogen activator inhibitor 1 values.
All patients with chronic kidney disease demonstrated higher levels of inflammatory parameters with respect to the 25 age-matched controls with normal renal function.
The researchers concluded that atorvastatin treatment improves the inflammatory state of these patients without modifying fibrinolytic balance.
[Study title: Beneficial Effects of Atorvastatin on Inflammatory Parameters in Patients with Chronic Kidney Disease (CKD). Abstract 955]
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
